Randomized multicenter trial of 3 weekly cabazitaxel versus weekly paclitaxel chemotherapy in the first-line treatment of HER2 negative metastatic breast cancer (MBC).Amit Bahl, William Wilson, Alicia Bravo et al.|Journal of Clinical Oncology|2021Cited by 2